

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (Currently Amended) A method for downmodulating an immune response comprising contacting immune cells from a subject with ~~at least one antibody that binds to at least one B7 molecule in combination with~~ a Rapamycin compound in combination with at least two antibodies, wherein each of said antibodies binds to a different B7 molecule selected from the group consisting of B7-1, B7-2, B7-H1, or B7RP-1.

Claim 2 (Canceled)

Claim 3 (Withdrawn) The method of claim 1, wherein the step of contacting is performed *ex vivo*.

Claim 4 (Previously Presented) The method of claim 1, wherein the step of contacting is performed *in vivo*.

Claim 5 (Currently Amended) A method for downmodulating an immune response in a subject having an autoimmune disorder comprising contacting immune cells from the subject with ~~at least one antibody that binds to at least one B7 molecule in combination with~~ a Rapamycin compound in combination with at least two antibodies, wherein each of said antibodies binds to a different B7 molecule selected from the group consisting of B7-1, B7-2, B7-H1, or B7RP-1.

Claim 6 (Canceled)

Claim 7 (Previously Presented) The method of claim 5, wherein the autoimmune disorder is systemic lupus erythematosus.

Claim 8 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to the subject an antibody that binds to B7-1, an antibody that binds to B7-2, and a Rapamycin compound, wherein the antibody that binds to B7-1 and the antibody that binds to B7-2 are administered over at least one short course of therapy.

Claim 9 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to the subject an antibody that binds to B7-1, an antibody that binds to B7-2, and a Rapamycin compound, wherein the Rapamycin compound is administered over at least one intermediate course of therapy.

Claim 10 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to said subject an antibody that binds B7-1, an antibody that binds B7-2, and a Rapamycin compound, wherein said Rapamycin compound is administered over at least one extended course of therapy.

Claim 11 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to said subject an antibody that binds B7-1, an antibody that binds B7-2, and a Rapamycin compound, wherein said Rapamycin compound is administered according to an early dosing regimen.

Claim 12 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to said subject an antibody that binds B7-1, an antibody that binds B7-2, and a Rapamycin

compound, wherein said Rapamycin compound is administered according to a late dosing regimen.

Claim 13 (Previously Presented) A method for downmodulating an immune response in a subject suffering from systemic lupus erythematosus comprising administering to said subject an antibody that binds B7-1, an antibody that binds B7-2, a Rapamycin compound, and an immunosuppressing agent, wherein said immunosuppressing agent is selected from the group consisting of FK506, Cyclosporin A and cyclophosphamide.